Back
bcrmut | 20821

TKI resistance BCR-ABL mutations

Keywords:
BCR-ABL mutations
MPN
imatinib resistance CML
myeloproliferative neoplasms

Status

Material
Blood EDTA EDTA tube, purple (6)
Hint

There is a possibility of excess information occurring with this analysis. This will be communicated, unless it is noted otherwise when placing the order. Since in rare cases there may also be indications of hereditary changes, the GUMG (Federal Law on Genetic Testing in Humans) provides for the patient to be informed accordingly (see www.viollier.ch/en/SGMG_consent).

Min. volume 4 mL
Stability
Stability
1 day / 2-8°C
Duration 3 days
Frequency 2 x per week

Price/Rate

Price
Price
CHF 0.00
Rate
Rate
0.00 TP

Executing laboratory

External laboratory